Monkeypox: What Clinicians Need to Know



Miranda Durham, MD Infectious Disease Bureau Medical Director July 21, 2022



Monkeypox Virus

- Monkeypox virus is an enveloped double-stranded DNA virus that belongs to the *Orthopoxvirus* genus of the *Poxviridae* family.
- There are two distinct genetic clades of the monkeypox virus: the Central African (Congo Basin) clade and the West African clade.
- The Congo Basin clade typically causes more severe disease
- US outbreak is West African clade



Monkeypox Virus

- Monkeypox was discovered in 1958 in research monkeys in a lab in Copenhagen, Denmark
- First human case was reported in 1970 in a 9 month old in DRC
- First case reported outside of Africa was in 2003 in a 3yo in the US



Credit: UK Health Security Agency/Science Photo Library

2003 US Outbreak

47 human cases; 6 states

People became ill after contact with pet prairie dogs infected after exposure to small mammals imported from West Africa

No cases attributed exclusively to person-to-person contact

First reported human monkeypox cases outside of Africa



CDC's restriction on the importation of African rodents remains in place

1190 S. St. Francis Drive • Santa Fe, NM 87505 • Phone: 505-827-2613 • Fax: 505-827-2530 • nmhealth.org

Natural host of monkeypox virus

Various animal species have been identified as susceptible to monkeypox virus including:

- Rope squirrels
- Tree squirrels
- Gambian pouched rats
- Dormice
- Non-human primates
- Anteaters
- Hedgehogs
- Prairie dogs
- Shrews
- other species

Further studies are needed to identify the exact animal reservoir(s) and how virus circulation is maintained in nature.

2022 U.S. Map & Case Count

MONKEYPOX

Updated July 20, 2022 Print

2,323 US cases

New York	581
California	356
Florida	208
Illinois	208
Georgia	156
D.C.	110



https://www.cdc.gov/poxvirus/monkeypox/response/2022/us-map.html



Figure 6: Age and gender distribution of cases of monkeypox, European Region, TESSy, 2022



https://www.who.int/europe/publications/m/item/joint-ecdc-who-regional-o

ffice-for-europe-monkeypox-surveillance-bulletin--13-july-2022

Overall by date of notification

Figure 1: Overall number of cases of monkeypox, per date of notification, European Region, TESSy, 2022



https://www.who.int/europe/publications/m/item/joint-ecdc-who-regional-o ffice-for-europe-monkeypox-surveillance-bulletin--13-july-2022

Monkeypox Transmission

The virus can spread from person-to-person through:

- direct contact with the infectious rash, scabs, or body fluids
- respiratory secretions during prolonged, face-to-face contact, or during intimate physical contact, such as kissing, cuddling, or sex
- touching items (such as clothing or linens) that previously touched the infectious rash or body fluids
- pregnant people can spread the virus to their fetus through the placenta

It's also possible for people to get monkeypox from infected animals, either by being scratched or bitten by the animal or by preparing or eating meat or using products from an infected animal.

Disease Progression

- Incubation is up to 21 days but usually 5 -12 days
- Monkeypox can spread from the time symptoms start until the rash has fully healed and a fresh layer of skin has formed.
- The illness typically lasts 2-4 weeks.
- People who do not have monkeypox symptoms cannot spread the virus to others.



Symptoms

The average time between symptom onset and diagnosis was 7 days.

Figure 7: Distribution of symptoms among those reporting at least one type of symptom (N=3683), European Region, TESSy, 2022



SYMPTOMS

Symptoms of monkeypox can include:

- Fever
- Headache
- Muscle aches and backache
- Swollen lymph nodes
- Chills
- Exhaustion
- A rash that can look like pimples or blisters that appears on the face, inside the mouth, and on other parts of the body, like the hands, feet, chest, genitals, or anus.

The rash goes through different stages before healing completely. Sometimes, people get a rash first, followed by other symptoms. Others only experience a rash.



Investing for tomorrow, delivering today.





1190 S. St. Francis Drive • Santa Fe, NM 87505 • Phone: 505-827-2613 • Fax: 505-827-2530 • nmhealth.org

Visual Examples of Monkeypox Rash









Monkeypox Lesions

Not Monkeypox









Clinical Features of May 2022 Outbreak

- Rash or enanthem in all patients
- Lesions in different phases of development seen side-by-side
- Rash either scattered or diffuse; sometimes limited to one body site and mucosal area (e.g., anogenital region or lips/face)
- Presenting complaint sometimes anorectal pain or tenesmus; physical examination yields visible lesions and proctitis
- Prodromal symptoms mild or not occurring
- Fever, lymphadenopathy not occurring in all patients
- Some co-infections with sexually transmitted infections

CDC Guidance to Clinicians - When to Test

HISTORY is Key!

- Observation of classic monkeypox rash
- Observation of rash that could be consistent with monkeypox in people with epidemiologic risk factors:
 - Contact with a person with similar appearing rash diagnosed with monkeypox
 - Close or intimate in-person contact with people in a social network experiencing monkeypox activity (e.g., men who have sex with men who meet partners through an online website, digital app or social event)
 - History of recent international travel to country currently reporting cases: <u>https://wwwnc.cdc.gov/travel/notices/</u>
- When lesions are not consistent with classic lesions, full body skin exam should be done to evaluate whether some classic lesions are observed
- Diagnosis of STI does not rule-out co-infection with monkeypox
- Call NMDOH: 505-827-0006

Testing

- 1. Call NMDOH ERD 505-827-0006
- 2. Use personal protective equipment (PPE) for standard, contact, and droplet precautions. (N95 mask, eye protection, gown, gloves)
- 3. If the patient has multiple lesions, swab up to 4 lesions, preferably from different locations on the body and/or from lesions with differing appearances.
- 4. Vigorously swab each lesion **with two** separate sterile dry polyester or Dacron swabs (one sample for preliminary and one for confirmatory testing at CDC). Do not use cotton swabs.
- 5. Place each swab in a separate "sterile" container such as a urine cup or pour-off tube (plastic preferred).
- 6. Do not add or store in viral or universal transport media.
- Each lesion site that is sampled requires a separate test requisition form. Put both samples from one site in the biohazard bag with one requisition. <u>https://www.nmhealth.org/publication/view/form/6380/</u>
- 8. Immediately refrigerate samples (2-8°C)
- 9. NMDOH will provide shipping instructions.





TESTING for Monkeypox

EW MEXICO SLD CL	Scientific La	EST REQUEST aboratory Division	FORM	SLD LAB NO. ONLY ONE FORM PER SPECIMEN
		no de Salud N.E. que. NM 87102		PLEASE PRINT LEGIBL
		ddemiology)	52325 (PHD: Adu	
D Form 101 w4.0 Revised 12/2) USER CODES ++		HD: General)	52330 (PHD: TB	
D DATE	-	ID: Prenatal)	51006 (EIP)	to one code
SE >>> << <time< td=""><td></td><td>ID: Family Plan)</td><td>70704 (OMI)</td><td>per form</td></time<>		ID: Family Plan)	70704 (OMI)	per form
NLY STAMP	-	HD: Refugee)	Other: (Enter Nur	
SUBMITTER INFORMATION	52340 (Pr	nD. Relugee)	PATIENT INFORM	
JEMITTER CODE	DAT	TENT NAME	Trinciti an ora	inion.
	PAI	IENT NAME	Last	Dat
ACILITY NAME	GEN			
	217		W/ DD/ YYYY :/	
ADDRESS	1000		W/ DD/ 1111/	
ADDRESS	ADD	Street or PO	0	
Diffeet of PO		Street of PO	Ĩ.	
City State Zip (Code	Phone Number	City	State Zip Dode
PHONE ()		TENT ID (MRN#)		
		CIAL SECURITY		
TENTION:		HER ID (HIV#)		
TENTION.	- 017	(mon)		
and the second			RACE: Check all the	
LINICIAN NAME	_ P	American Indian/Alas	skan Native 📃 Asi	an 🔄 Black/African American
PHONE # ()		Native Hawalian/Pac	the Islandar un	te Other
-mone # ()				
			ispanic No	n-Hispanic
		INFORMATION		
Abscess Bronchial Biopsy S Ascites fluid Bronchial Wash	Har	1 (site):	Nasal wash Pericardiai fluid	Sputum, nebulized
O Blood, femoral Bronchoalveolar lavao			Peritoneal fuid	Throat wash
U Blood, heart Cervix	Lym	ph node	Pleural fluid	Tissue (site):
R Blood, plasma CSF	Lung	g, left	Pleural Blopsy	Tracheal aspirate
C Blood, serum Ear		g, right	Rectum	Urine
E Blood, whole Endocervix Bone Eye		(site) opharyngeal swab	Rectum/Vagina Skin (site)	Urethra Vagina
Bone marrow Feces/Stool		opharyngeal wash	Spleen	Wound (site):
Brain Genital		al swab	Sputum, natural	Other.
SPECIMEN COLLECTION		SPECIMEN TYPE	CL	NICAL SYMPTOMS
		Clinical	Asymptomatic	
ate/Time Collected//				
MM/ DD/ YYYY Military Time	e 🗌	Reference	Symptomatic:	Date of onset: MM / DD / YYYY
				1 1
		QUESTED		org/publication/view/general/1496/
BACTERIOLOGY N. meningitidis t	pring	Arbovirus ID		org/publication/view/general/1496/ Hepatitis A,B and C Diagnostic
BACTERIOLOGY N. meningitidis t B. anthradis Plague FA and d	typing culture	Arbovirus ID CDC referra) Il (attach form 50.34)	org/publication/view/general/1496/ Hepatitis A,B and C Diagnostic Panel (Acute)
BACTERIOLOGY N. meningitids to B. anthradis Plague FA and O B. cereus/S. aureus Saimonella, sero Culture, OMI Shigelia, serotyp	typing culture type: e:	Arbovirus ID CDC referra HIV Ag/Ab 0 Hepatitis A 1) il (attach form 50.34) Combo with Reflex Diagnosis (IgM Only)	rogipublicationViewgeneral/1496/ Hepatitis A, B and C Diagnostic Panel (Acute) Mumps Immune Status Plaque/Tularemia antibody
BACTERIOLOGY N. meningitidis t B. anthradis Plague FA and o B. cereus/S. aureus Samonella, sero Cuture, OMI Shigela, serotyp Cuture, OMI anaerobic Shiga Toxin test	yping culture type: e: Isolation	Arbovirus IE CDC referra HIV AgiAb 0 Hepatitis A 1 Hepatitis A 1) il (attach form 50.34) Combo with Reflex Diagnosis (IgM Only) Immune Status	torgpublicationViewgeneral/1496/ Hepatitis A,B and C Diagnostic Panel (Acute) Mumps Immune Status Plague/Tularemia antibody Rubella Immune status
BACTERIOLOGY N. meningtids t B. antinads Pague FA and C. B. oerus:S. aureus Samuela, sero Culture, OMI Shiga Taxin test Campiocater species: Tutarenta culture	yping culture type: e: Isolation	Arbovirus ID CDC referra HIV AgiAb 0 Hepatitis A 1 Hepatitis A Hepatitis B) I (attach form 50.34) Combo With Reflex Diagnosis (IgM Only) Immune Status Pre-Vaccination	orgipublication Viewgeneral/1496/ Hepatitis A, B and C Diagnostic Panel (Acute) Mumps Immune Status Plaque-Tularemia antibody Rubella Immune status Rubella diagnosis (call first)
BACTERIOCOCY N. meningidis B. antinadis Plague FA and B. cereusici, aureus Samonella, sero Cuture, OMI anaerobic Singela, seroty Cuture, OMI anaerobic Singela, architesi Campitocater species: Tularenta olture E. coli 057:H7 Vibrio	yping culture type: e: (solation e	Arbovirus IE CDC referra HIV Ag/Ab 0 Hepatitis A I Hepatitis B Hepatitis B Hepatitis B) il (attach form 50.34) Combo with Reflex Diagnosis (IgM Only) Immune Status Pre-Vaccination Prevatal Screen	org publication Viewgeneral 1456/ Hepatitis A.B. and C. Diagnostic Panel (Acute) Viumps Immune Status Plague/Tularema antibody Rubeila Immune status Rubeila Immune status
BACTERIOLOGY N. memigitis P. B. arthroads Plaque FA and C. B. ostraustic auraus Samonella, sero Cuture. ONI anaerosic Singela, serotyp Cathyre. ONI anaerosic Singela, serotyp Cathyre.oNI anaerosic Tutaremia cuture E. Coll 0157:H7 Vbno EIP Group A Ofstptococcut	yping culture type: e: (solation e	Arbovirus IE CDC referra HIV Ag/Ab 0 Hepatitis A I Hepatitis B Hepatitis B Hepatitis B	(attach form 50.34) Combo with Reflex Diagnosis (igM Only) Immune Status Pre-Vaccination Prenatal Screen Post-Vaccination	vorgpublication/vewgeneral/456/ Hepatitis A, B and C Diagnostic Panei (Acute) Mumps Immune Status Plague/Tutaremia antibody Rubeila immune status Rubeila diagnosis (cali first) Rubeila immune status Rubeila ingnosis (cali first)
BACTERIOLOGY N. memigitis 5 B. anthroas B. anthroas Cuture. CNI anarosis Cuture. CNI anarosis Cataryo CNI anarosis	yping culture e: isolation e olitica:	Arbovirus IC CDC referra HIV AgiAb 0 Hepatitis A Hepatitis B Hepatitis B Hepatitis B Hepatitis B Hepatitis B Hepatitis B Hepatitis B) II (attach form 50.34) Combo with Reflex Diagnosis (igM Only) Immune Status Pre-Vaccination Prenatal Screen Post-Vaccination	corpublication/viewgeneral/456/ Hepatilis A,B and C Diagnostic Panel (Acute) J Wumps Immune status Plaguer/Tuarenki antbody Rubelia Immune status Rubelia Immune status Rubeola Immune status Rubeola diagnosis (call first) Rubeola diagnosis (call first) SNV Hantartus
BACTERIOLOGY N. memigidis Pague FA and B. anthnais B. anthnais Samonella, sero Cutare, ONI Cu	yping outure e: fsolation e olitica: S/MYCOLOGY	Arbovirus IC CDC referra HIV AgiAb 0 Hepatitis A Hepatitis B Hepatitis B Hepatitis B Hepatitis B Hepatitis B Hepatitis B Hepatitis B	(attach form 50.34) Combo with Reflex Diagnosis (igM Only) Immune Status Pre-Vaccination Prenatal Screen Post-Vaccination	corpublication/ewgeneral/1490 Hepathis A B and C Diagnostic Panel (Acute) Panel (Acute) Pague/Tutaremin antbooty Rubelia immune status Rubelia immune status Rubelia diagnosis (call first) Rubelia diagnosis (call first) ShVH Hartashti Refex to TPF Synthis RPR with Refex to TPF Synthis RPR with Refex to TPF
BACTERIOLOGY N. meningside : B. anthroads . B. anthroads . S. annowida, serectly Cutary: of all anaerosis . Caranysidoacter species . Tutaremis acuture E. coll 0157:H7 Volto EIP Group A Streptococcus . Cherrical . Caranysidoacter species . EIP Group A Streptococcus . Cherrical . Caranysidoacter species . Coll 1057:H7 Volto . EIP Group A Streptococcus . Cherrical . Caranysidoacter species . Coll 1057:H7 Volto . EIP Group A Streptococcus . Cherrical . Coll 1057:H7 Volto . C	yping outure e: fsolation e olitica: S/MYCOLOGY	Arbovirus IC CDC referra HIV AgiAb 0 Hepatitis A Hepatitis B Hepatitis B Hepatitis B Hepatitis B Hepatitis B Hepatitis B Hepatitis B	(attach form 50.34) Combo with Reflex Diagnosis (IgM Only) Immune Status Pre-Vaccination Prenatal Screen Post-Vaccination High Risk and HOV	urgpublication/lewgeneral/1499/ Thegatilis A, B and C Tuagnostic Panel (Acute) Journes Immune Status Plaque/Tuagent antibooty Rubelia Immune status Rubelia Immune status Rubelia Immune status Rubelia Immune status Rubelia Immune status Synkii Rore Muth Refex to TPPA Synkiis Rore Muth Refex to TPPA Synkiis Rore Muth Refex to TPPA Synkiis Rore Muth Refex to TPPA
BACTERIOLOGY N. mengidis 5 Bactmas Bacture, ONI B. antimats Cubre, ONI	sping suture e fisciation e olitica: SIMYCOLOGY ycetes	Arbovins IC CDC referra HIV AgAb 0 Hepattis A Hepattis B Hepattis B Hepattis B Hepattis B Hepattis B Hepattis B Hepattis C) ((attach form 50.34) Chagnosis (igM Crity) Inmune Statas Pre-Vaccination Prenatal Soreen Post-Vaccination Hgh Risk Hgh Risk and HCV Antbody (Anti-HCV)	corpublication/leargeneral (460) Heightitis A, B and C Lagnostic Panel (Acute) Panel (Acute) Panel (Acute) Hayaer Tutaremin antibody Rubela immune status Rubela immune status Rubela diagnosis (call first) ShVH Haritarth Refer. to TPP Synthis RPR with Refer. to TPP
BACTERIOLOGY N. memigitis 5 B. arthrods Pague FA and C. B. ostrust. auraus Samonella, seroly Cuture. ONI anaerosic Singelia, seroly Catropicoder species. Campylocaler species. Tutaremin auture E. coll 0157-hr Voho EIP Group 5. Oteppoocous EIP Group 5. Oteppoocous EIP Group 5. Oteppoocous EIP Group 5. Oteppoocous EIP Coutare Managements Haemophilus intuesza typica. Aerosc. actinomy Lastera monocytogeness E docutare outre	yping outure e: solation e oiltica: SIMYCOLOGY yoetes solate	Arbovirus IC CDC referra HIV AgiAb 0 Hepatitis A Hepatitis B Hepatitis B Hepatitis B Hepatitis B Hepatitis B Hepatitis B Hepatitis B) ((attach form 50.34) Chagnosis (igM Crity) Inmune Statas Pre-Vaccination Prenatal Soreen Post-Vaccination Hgh Risk Hgh Risk and HCV Antbody (Anti-HCV)	urgpublication/lewgeneral/1499/ Thegatilis A, B and C Tuagnostic Panel (Acute) Journes Immune Status Plaque/Tuagent antibooty Rubelia Immune status Rubelia Immune status Rubelia Immune status Rubelia Immune status Rubelia Immune status Synkii Rore Muth Refex to TPPA Synkiis Rore Muth Refex to TPPA Synkiis Rore Muth Refex to TPPA Synkiis Rore Muth Refex to TPPA
BACTERIOLOGY N. memorgidis B B. anthnads Pague FA and O B. oversiti. auraus Samonella, sero Cubre. OM snareotic in Cubre. OM snareotic in E. col 1057:47 Vetro EP Group A Streptococus Yersinia entoro EP Group 5 Streptococus Officer Haemophius influenza typing Aeroic automos Lateria monostogenes Lagionella cubre AFB Reference II Suppered Discourse AFB Reference II Suppered Discustore	yping outure e: solation e oiltica: SIMYCOLOGY yoetes solate	Arbovins IC CDC referra HIV AgAD C Hepatits A Hepatits A Hepatits A Hepatits B Hepatits B Hepatits B Hepatits B Hepatits C Hepatits C	() (attach form 50.34) Combo with Reflex Chagnosis (gM Crity) Immune Statas Pre-Vaconation Prenatal Soreen Post-Vacotination Hgh Risk and HCV Antibody (Anti-HCV)	urgipublication/vergeneral/149/ Hepatits X,B and C Dagnostic Panel (Acuts) Murging immune Status Page Tuarema antibooy Rubella diagnostic (cal Inst) Rubedia diagnostic (cal Inst) Rubedia diagnostic (cal Inst) Rubedia diagnostic (cal Inst) Rubedia diagnostic (cal Inst) SIMH Hantanan Signitis RPR with Reflect to TPR Signitis RPR with
BACTERIOLOGY N. meningtide ' Paque FA and C B. antimate B. antimate Cuture. ONI anaerolo. Singela.serotyp Cuture. ONI anaerolo. Singela.serotyp Catryotocater species. Tutaremin acuture E. coll 0157:H7 Vitro EIP Group 5 Oreptococus EIP Group 5 Oreptococus EIP Contraction acuture Cuture.onit intercase typing Aerotoc aconom Aerotoc aconom Aerotoc aconom Aerotoc aconom Aerotoc aconom Aerotoc aconom APB Cuture Legionelia cuture Do facteria (specify) Expenditure acuture	sping suture itype:isolation e olitica: sMYCOLOGY ycetes solate	Arbovins IC CDC referra HIV AgAD C Hepatits A Hepatits A Hepatits A Hepatits B Hepatits B Hepatits B Hepatits B Hepatits C Hepatits C) ((attach form 50.34) Chagnosis (igM Crity) Inmune Statas Pre-Vaccination Prenatal Soreen Post-Vaccination Hgh Risk Hgh Risk and HCV Antbody (Anti-HCV)	urgpublication/leargeneral/1459/ Thegatilis A,B and C Lagranstic Panel (Acute) Juurge Immune Status Plaque/Tuatema antibody Rubela immune status Rubela immune status Rubela immune status SynNis RPR and TPPA SynNis RPR with Reflex to TPP SynNis RPR with Reflex to TPPA SynNis RPR with Reflex to TPPA SynNis RPR with Reflex to TPPA SynNis RPR and TPPA TB Quantiferon VZV immune status
BACTERIOLOGY N. memigidis Pague FA and c B. anthnois B. anthnois B. anthnois Cuture. ONI anarosice Singelia.serdyp Cuture. ONI anarosice Singelia.serdyp Campyodacter species Tutaremia cuture Campyodacter species Tutaremia cuture Campyodacter species Tutaremia cuture PiP Grup B Otteptooccus EIP Grup B Otteptooccus EI	sping suture hype: isolation e olitica: simyCOLOGY yoetes solate	S Hepatits A Hepatits A Hepatits A Hepatits A Hepatits A Hepatits B Hepatits B Hepatits B Hepatits B Hepatits B Hepatits B Hepatits C Other (Spec 2019 Novel	() (attach form 50.34) Combo with Reflex Chagnosis (gM Crity) Immune Statas Pre-Vaconation Prenatal Soreen Post-Vacotination Hgh Risk and HCV Antibody (Anti-HCV)	urgipublication/evergeneral/459 Hepaths A,B and C Loggnostic Panel (Acute) Murging immune Status Hegger Tuaema antibody Rubella diagnosis (call Inst) Rubela diagnosis (call Inst) Sphills RPR with Refex to TPP Sphills RPR with Refex to TPP Sphi
BACTERIOLOGY N. meningtide ' Pague FA and c B. antimats Samonella, sere Cuture. CNI anaeroic. Singela, serotyp Cuture. CNI anaeroic. Singela, serotyp Catrypicodict species. Tutaremia cuture Campiolocate species. Tutaremia externa Construction Somptone Somptone Singela, serotyp Catrypicodict species. Tutaremia externa Construction Somptone Construction Singela, serotyp Catrypicodict species. Tutaremia externa Construction Constructio	sping suture hype: isolation e olitica: simyCOLOGY yoetes solate	Advortus II COC reference Hepatits A Hepatits A Hepatits A Hepatits B Hepatits B Hepatits B Hepatits B Hepatits B Hepatits B Hepatits C Other (Spec V I R	I attach ten 63.34 Conto with Reflex Daprose (gW Orly) Immune Status Per-Vaconation Per-Vaconati	Lagrabitis X,B and C Lagrassic Panel (Acts) Murge Immune Status Panel (Acts) Ruper Lagramment attus Rupela diagnosis (cal fins) Rupeda diagnosis (cal fins) Rupeda diagnosis (cal fins) SMM Hantarium status Publica diagnosis (cal fins) Synthis RPR with Reflex to TPP Synthis RPR wi
BACTERIOLOGY N. memigitis 5 B. arthrods Pague FA and C. B. ostraustic auraus Samonella, seroly Cuture. ONI anaerosic. Singela, seroly Cataryeloader species. Truisremia cuture E. coll 0157:H7 Votro EIP Group 5 Oreptoocous EIP Conume 5 Oreptoocous EIP Couter Content Control Content Go cuture Go cuture Go cuture Haemophilus intuenza typica Haemophilus intuenza typica Catinomy Artific collare Gram positive Gram positive Caram positive Contare Content D G Bacteria (specify) Anaerobe Gram positive Caram positive Cara	pping puture eisolation e solation solatica: SMYCOLOGY yoetes solate ture ference isolate	Attorvinus II COC refera Hepatits A Hepatits A Hepatits A Hepatits A Hepatits B Hepatits B Hepatits B Hepatits C Other (Spec Cother (Spec Cother (Spec Cother (Spec V I us Isoli	attach from 50.34) Combo With Reflex Disproses (gW Chy) Immune Gabase Rev-Vacionation Prentatal Greenen Prentatal Greenenenenenenenenenenenenenenenenenene	corpublication/keurgeneal/1499 Heightills A,B and C Lagnostic Panel (Acuts) Panel (Acuts) Panel (Acuts) Panel (Acuts) Rubela immune Status Rubela immune status Rubela immune status SMM Hantavirus SMM Hantavirus SMM RPR with Reflex to TPPA Synhile RPR with Reflex to TPPA (Per Epidemiology Guidance)
BACTERIOLOCY IN meningside : Bactradia : Bact	pping puture (hype:	V ADDAVIUS IS COC referant Heyattis A Heyattis A Heyattis B Heyattis B Heyattis B Heyattis B Heyattis B Heyattis C Other (Spec V I R O Virus Isolit Addavia I Virus Isolit Virus Iso	attach tem 50.34) Combo with Reflex Combo with Reflex Chaptoss (gM orby) Immune Cabas Per-Jaconationation Per-Jaconationation Per-Jacon	ungbabitatoriveurgeneal (49) Hepatis X,B and C Dagnosto Panel (Acuts) Murge timmune Status Hegae Tuarens antibody Rubels immune status Hebeda disprossi (cal first) DNH Hantarium status Public RPR with Reflect to TPR Ophilis RPR state to
BACTERIOLOGY N. memigidis B. arthrads Pague FA and C. B. arthrads Sammelia, serdy Cature, ONI Sammelia, serdy Cature, ONI Singelia, serdy Cature, ONI Singelia, serdy Cature, ONI Singelia, serdy Campidoafer species: Tutarentia cuture E. Coll 0157:H7 Who EIP Group B Streptomocus Ofter EIP Group B Streptomocus Ofter EIP Columentale isolate Aerooc actinomy Labera outure Suspected ID Istera monocytogenes AFE Cuture Legionels outure Suspected ID Gram positive Suspected ID Program Resetance Suspected ID Program Costive Suspected ID Partition Resetance Persussi (Boreet)	pping puture (hype:	A ADOVINUE I COC refers Hepatits A I R Hepatits B I Hepatits B I Hepatits B I Hepatits B I Hepatits B I Hepatits B I O Hepatits B I O Hepatits B I O Hepatits C I O Other (Spec O Other (Spe	attach tem 50.34) Combo with Reflex Combo with Reflex Chaptoss (gM orby) Immune Cabas Per-Jaconationation Per-Jaconationation Per-Jacon	corpublication/kengeneal/459 Heightlis A,B and C Lagnostic Parel (Autilie Parel (Autilie Parel (Autilie Parel (Autilie Parel (Autilie Parel (Autilie) Rubela algoration (call first) Rubela immune status Rubela immune status Shubela Agnossis (call first) Rubela immune status Shubela Agnossis (call first) Rubela immune status Shubela Agnossis (call first) Shubela Agnossis (call first) Rubela Immune status Shubela Agnossis (Per Epidemiology Guidance) Rapid Test: Pos_Neg_ Not Performed_ Dengue/Chikungunya PCR
BACTERIOLOGY A memigitials B.achinas B.achinas B.achinas B.achinas Cautare. OMI anaerote. Singela.serotyp Cautare. OAI anaerote. Singela.serotyp Cautare. OAI anaerote. Singela.serotyp Cautare.oAI anaerote. Singela.serotyp Aeroto.caure Ladoratina cuture Do flacteria (specify) Araerote.caure Suspectial TO. Argela.serotyp Araerote.eaure Caram registre Caram registre Caram logetite Caram positie. Suspectial TO. Montercut Resettance Montercut Resettance Montercut Resettance Montercut Resettance Montercut Resettance Montercut	pping puture (hype:	Arbovitus II COC refera Hepatits A E Hepatits A E Hepatits B D Hepatits B C Hepatits B Hepatits B C Hepatits B Hepatits B C Hepatits B Hepatits C C C Hepatits A Hepatits B C Hepatits B C C Hepatits B C C C C C C C C C C C C C	a attorn tem 50.34) Combo with Refere. Combo with Refere. Catoproses (gM orby) Intrimume Catabas. Pre-vascination Pre-v	ungbabitatoriveurgeneal (49) Hepatis X,B and C Dagnosto Panel (Acuts) Murge timmune Status Hegae Tuarens antibody Rubels immune status Hebeda disprossi (cal first) DNH Hantarium status Public RPR with Reflect to TPR Ophilis RPR state to

Commercial Labs that do Monkeypox testing





https://www.labcorp.com/infectious-disease/monkeypox

https://www.questdiagnostics.com/healthcare-professional s/about-our-tests/infectious-diseases/monkeypox

TREATMENT of Monkeypox

- Tecovirimat (also known as TPOXX, ST-246)
- Requested from CDC/SNS
- Indications: Patients with monkeypox with immune compromise, lesions in mouth/genitals or around the eyes
- Clinical trials in people showed the drug was safe and had only minor side effects.
- FDA approved for smallpox, but not monkeypox
- CDC holds an expanded access protocol (sometimes called "compassionate use") that allows for the use of stockpiled tecovirimat to treat monkeypox during an outbreak.
- Tecovirimat is available as a pill or an injection.
- For children who weigh less than 28.6 pounds, the capsule can be opened, and medicine mixed with semi-solid food



Other treatments for Monkeypox

• Vaccinia Immune Globulin Intravenous (VIGIV)

VIGIV is licensed by FDA [PDF - 18 pages]

VIG can be considered for prophylactic use in an exposed person with severe immunodeficiency in T-cell function for which smallpox vaccination following exposure to monkeypox virus is contraindicated.

• Cidofovir (also known as Vistide)

Cidofovir is an antiviral medication that is <u>approved by the FDA [PDF - 6 pages]</u>

for the treatment of cytomegalovirus (CMV) retinitis in patients with Acquired Immunodeficiency Syndrome (AIDS). Data is not available on the effectiveness of Cidofovir in treating human cases of monkeypox.

• Brincidofovir (also known as CMX001 or Tembexa)

Brincidofovir is an antiviral medication that was <u>approved by the FDA [PDF – 21 pages]</u>

on June 4, 2021 for the treatment of human smallpox disease in adult and pediatric patients, including neonates. Data is not available on the effectiveness of Brincidofovir in treating cases of monkeypox in people. Not currently available.

CDC VACCINE STRATEGY

- 1. Monkeypox Vaccine Post-Exposure Prophylaxis (PEP):
 - "Standard PEP" for monkeypox.
 - People can be vaccinated following exposure to monkeypox to help prevent illness from monkeypox virus.
- 2. Outbreak Response Monkeypox Vaccine Post-Exposure Prophylaxis (PEP)++:
 - expanded PEP" or "PEP plus-plus" or "PEP++".
 - Vaccinate people who are more likely to have been recently exposed to monkeypox even if they have not had documented exposure to someone with confirmed monkeypox
- 3. Monkeypox Vaccine Pre-Exposure Prophylaxis (PrEP):
 - vaccine people at high risk for monkeypox (for example, laboratory workers who handle specimens that might contain monkeypox virus).
 - Most providers do not need vaccination



https://www.cdc.gov/poxvirus/monkeypox/clinicians/smallpox-vaccine.html

Investing for tomorrow, delivering today.



1190 S. St. Francis Drive • Santa Fe, NM 87505 • Phone: 505-827-2613 • Fax: 505-827-2530 • nmhealth.org

CDC VACCINE STRATEGY

Post Exposure Prophylaxis

- CDC recommends that the vaccine be given within 4 days from the date of exposure for the best chance to prevent onset of the disease.
- If given between 4 and 14 days after the date of exposure, vaccination may reduce the symptoms of disease, but may not prevent the disease.
- New Mexico has vaccine on hand for PEP



Investing for tomorrow, delivering today.



JYNNEOS VACCINE for Monkeypox

- JYNNEOS is a live, attenuated, non-replicating virus vaccine
- FDA approved in 2019 for prevention of smallpox and monkeypox disease in adults 18+
- Two doses given four weeks apart.
- Administered subcutaneously
- Single dose vial (0.5mL)
- Most common side effectS: injection site reactions (pain, redness, swelling, induration, itching), muscle pain, headache, fatigue, nausea, myalgia, chills



ACAM2000

- FDA approved for prevention of smallpox disease in high risk people
- Replication-competent vaccinia virus
- Complications from the vaccinia virus can be severe in immune compromised people
- Can be transmitted from the vaccine recipient to unvaccinated persons who have close contact with the inoculation site
- ACAM2000® is administered as a single dose by the percutaneous route using the multiple puncture technique.
- The **2015 ACIP recommendations** advise routine vaccination of laboratory personnel who directly work with orthopox viruses.











Day 14

Day 21



Investing for tomorrow, delivering today.



Evaluating Exposures

• In general:

Transmission of monkeypox requires prolonged close contact with a symptomatic individual. Brief interactions and those conducted using appropriate PPE in accordance with Standard Precautions are not high risk and generally do not warrant PEP

• Call NMDOH: 505-827-0006 (epidemiology on call)

Monitoring Exposed Healthcare Professionals

Any healthcare worker who has cared for a monkeypox patient should be alert to the development of symptoms that could suggest monkeypox infection, especially within the 21 day period after the last date of care, and should notify infection control, occupational health, and the health department to be guided about a medical evaluation.

Healthcare workers who have unprotected exposures (i.e., not wearing PPE) to patients with monkeypox do not need to be excluded from work duty, but should undergo active surveillance for symptoms, which includes measurement of temperature at least twice daily for 21 days following the exposure. Prior to reporting for work each day, the healthcare worker should be interviewed regarding evidence of fever or rash.

Healthcare workers who have cared for or otherwise been in direct or indirect contact with monkeypox patients while adhering to recommended infection control precautions may undergo self-monitoring or active monitoring as determined by the health department.

Degree of Exposure: High

Recommendations

- Monitoring[§]
- PEP[¶] Recommended

Exposure Characteristics

- Unprotected contact between a person's skin or mucous membranes and the skin, lesions, or bodily fluids from a
 patient (e.g., any sexual contact, inadvertent splashes of patient saliva to the eyes or oral cavity of a person, ungloved
 contact with patient), or contaminated materials (e.g., linens, clothing) -OR-
- Being inside the patient's room or within 6 feet of a patient during any procedures that may create aerosols from oral secretions, skin lesions, or resuspension of dried exudates (e.g., shaking of soiled linens), without wearing an N95 or equivalent respirator (or higher) and eye protection -OR-
- Exposure that, at the discretion of public health authorities, was recategorized to this risk level (i.e., exposure that ordinarily would be considered a lower risk exposure, raised to this risk level because of unique circumstances)

Degree of Exposure: Intermediate

Recommendations

- Monitoring[§]
- PEP[¶] Informed clinical decision making recommended on an individual basis to determine whether benefits of PEP outweigh risks ^{¶¶}

Exposure Characteristics

- Being within 6 feet for 3 hours or more of an unmasked patient without wearing, at a minimum, a surgical mask -OR-
- Activities resulting in contact between sleeves and other parts of an individual's clothing and the patient's skin lesions or bodily fluids, or their soiled linens or dressings (e.g., turning, bathing, or assisting with transfer) while wearing gloves but not wearing a gown -OR-
- Exposure that, at the discretion of public health authorities, was recategorized to this risk level because of unique circumstances (e.g., if the potential for an aerosol exposure is uncertain, public health authorities may choose to decrease risk level from high to intermediate)

Degree of Exposure: Low/Uncertain

Recommendations

- Monitoring⁵
- PEP¹ None

Exposure Characteristics

- Entered the patient room without wearing eye protection on one or more occasions, regardless of duration of exposure -OR-
- During all entries in the patient care area or room (except for during any procedures listed above in the high-risk category), wore gown, gloves, eye protection, and at minimum, a surgical mask -OR-
- Being within 6 feet of an unmasked patient for less than 3 hours without wearing at minimum, a surgical mask -OR-
- Exposure that, at the discretion of public health authorities, was recategorized to this risk level based on unique circumstances (e.g., uncertainty about whether Monkeypox virus was present on a surface and/or whether a person touched that surface)

Degree of Exposure: No Risk

Recommendations

- Monitoring⁵ None
- PEP¹ None

Exposure Characteristics

Exposure that public health authorities deemed did not meet criteria for other risk categories

Monkeypox | NMHealth.org

	НОМЕ	NEWSROOM	EVENTS	PUBLICATIONS	HEALTH DATA	CONTACT	HELP	COVID-19 UPDATES	(f) 💌 (in) 🗵
WHAT WE DO	YOUR HEA	LTH MOST	POPULAI	R LOCATIO	NS ABOUT	имдон	Α ΤΟ Ζ		۵

A Home » Divisions » Public Health » Infectious Disease Prevention » Monkeypox

MENU

Monkeypox

News

Publications

Resources

NEW MEXICO DEPARTMENT OF HEALTH

Monkeypox Virus

Overview

Monkeypox is a rare disease caused by infection with the monkeypox virus. It was first discovered in 1958 when there were two outbreaks of a pox-like disease in colonies of monkeys kept for research. The first human case was in 1970. Prior to 2022, nearly all U.S. cases were related to international travel. <u>Monkeypox: Get The Facts Poster (English)</u>

Monkeypox: Get The Facts Poster (Spanish)





Investing for tomorrow, delivering today.

1190 S. St. Francis Drive • Santa Fe, NM 87505 • Phone: 505-827-2613 • Fax: 505-827-2530 • nmhealth.org





Monkeypox: Get the Facts

Monkeypox is a rare disease caused by the monkeypox virus

. Monkeypox can make you sick including a rash or sores (pox), often with an earlier flu-like illness

Monkeypox can spread to anyone through close, personal, often skin-to-skin contact including:

Direct contact with monkeypox rash, sores or scabs

- Contact with objects, fabrics (clothing, bedding, or towels), and surfaces that have been used by someone with monkeypox
- Through respiratory droplets or oral fluids from a person with monkeypox

This contact can happen during intimate sexual contact including:

- Oral, anal, and vaginal sex
- Hugging, massage, or mutual masturbation
- Kissing and talking closely
- Touching fabrics and objects during sex that were used by a person with monkeypox, such as bedding, towels and sex toys

 We know the virus can be spread in fluid or pus from monkeypox sores, and are trying to better understand if virus could be present in semen or vaginal fluids

What Are the Symptoms?

Early flu-like symptoms of monkeypox can include:

Fever
 Headache
 Muscle aches and backache
 Swollen lymph nodes
 Chills
 Exhaustion



 A rash or sores, sometimes located on or near the genitals or anus, but sometimes in other areas like the hands, feet, chest or face – sores will go through several stages before healing

Sores may be inside the body, including the mouth, vagina, or anus

Some people experience a rash or sores first, followed by other symptoms and some only experience a rashor sores
 Monkeypox can be spread from the time symptoms start until all sores have healed and a fresh layer of skin has formed – this can take several weeks

If You Have a New or Unexplained Rash, Sores, or Other Symptoms...

See your healthcare provider – if you don't have a provider or health insurance, visit a
public health clinic near you

 When you see a healthcare provider for possible monkeypox, remind them that this virus is circulating in the community

. Avoid sex or being intimate with anyone until you have been checked out

If You or Your Partner Have Monkeypox...

Follow the treatment and prevention recommendations of your healthcare provider
 Avoid sex or being intimate with anyone until all your sores have healed and you have a fresh layer of skin formed.



For more information, please visit www.cdc.gov/monkeypox

CDC Monkeypox site:

https://www.cdc.gov/poxvirus/monkeypox/pdf/Monkey Pox-sexually-active-InfoSheet-508.pdf

NMDOH Monkeypox site:

https://www.nmhealth.org/about/phd/idb/mpv/



Summary

- While monkeypox cases continue to increase, risk to the general public is low with transmission primarily occurring among specific social networks
- Clinicians should be alert to potential monkeypox infections and call Epidemiology and Response Division 24/7 at (505)827-0006
- Testing for Monkeypox is available through the state public health lab (SLD) Quest Diagnostics, Labcorp, Aegis Sciences, Mayo Clinic Labs
- This is an evolving situation so new information continues to emerge
- NM expects to receive more doses of JYNNEOS in coming month.



NM Health Alert Network (HAN)

The NM Health Alert Network (HAN) is the NMDOH's communications platform that allows for rapid dissemination of important public health information to our key healthcare partners and emergency response personnel, on a 24/7/365 basis.

To receive health alerts directly to your email, sign up for the Health Alert Network (HAN)

https://nm.readyop.com/fs/4cjZ/10b2

Additional resources

- MAY 26, 2022 NMDOH HAN here <u>https://www.nmhealth.org/publication/view/general/7527/</u>
- JULY 8, 2022 HAN here <u>https://www.nmhealth.org/publication/view/general/7614/</u>
- There is also a page on the NMDOH website with monkeypox resources information for clinicians and the general public <u>nmhealth.org/Monkeypox</u>
- <u>cdc.gov/poxvirus/monkeypox</u>

DOH Contact Information for Providers

CONTACT INFO	DESCRIPTION
Epidemiology and Response Division 505-827- 0006	Epidemiologist on call for guidance on any reportable diseases (monkeypox, measles, rabies, etc)
COVID.Vaccines@state.nm.us	COVID-19 Vaccine Record requests; Provider COVID-19 Vaccine Order status; NMSIIS assistance.
COVID.Therapeutics@state.nm.us	Provider questions regarding COVID therapeutics
COVIDData.compliant@state.nm.us	COVID-19 vaccine storage and handling questions, temperature log and onboarding Vaccine Plan submissions.
COVID.testing-doh@state.nm.us	For Provider questions on testing and test supplies



Investing for tomorrow, delivering today.



1190 S. St. Francis Drive • Santa Fe, NM 87505 • Phone: 505-827-2613 • Fax: 505-827-2530 • nmhealth.org

DOH Contact Information for Patients

CONTACT INFO	DESCRIPTION
COVID-19 Hotline: 1-855-600-3453	Users who have questions or would like support with COVID vaccine registration and testing Taking Monkeypox questions
ALTSD assistance: 1-800-432-2080	For seniors and those with disabilities who need support with vaccine registration and scheduling.
1-833-551-0518	For non-health related COVID-19 questions



Investing for tomorrow, delivering today.



1190 S. St. Francis Drive • Santa Fe, NM 87505 • Phone: 505-827-2613 • Fax: 505-827-2530 • nmhealth.org



THANK YOU for all that you do!

Mexico City